Navigation Links
Depomed Reports Third Quarter Financial Results
Date:11/5/2012

DA accepted our NDA for Serada and set a tentative date for an Advisory Committee. We believe that we are well on our way toward transforming Depomed into a sustainably profitable specialty pharmaceutical company.  We are developing a pain franchise with our two marketed products, Gralise and Zipsor.  We have a Glumetza royalty stream that should exceed $40 million for 2012, a broad base of six license and development agreements that should provide us significant milestones and royalties over the next several years, a pipeline of product candidates and a strong balance sheet," said Jim Schoeneck, president and chief executive officer of Depomed.

Depomed Third Quarter Financial Highlights
Total revenue for the third quarter of 2012 was $33.3 million, consisting of $4.8 million of Gralise product sales, $4.9 million of Zipsor product sales, $12.2 million of royalties and $11.4 million of license and other revenue. License and other revenue includes recognition of the $10 million upfront payment received from Janssen under the license agreement for Nucynta ER.

This compares to revenues of $16.5 million in the third quarter of 2011. Third quarter 2011 revenues included $9.2 million of Glumetza product sales.  Revenues for third quarter 2012 do not reflect any Glumetza product sales as a result of the restructuring of the Santarus agreement in August 2011.  Prior to the restructuring of the agreement, Depomed recognized revenues and cost of goods from Glumetza sales and paid Santarus a promotion fee that was included in expenses.

Operating expenses were $33.1 million for the third quarter of 2012.  This compares with $24.7 million for third quarter 2011. Operating expenses increased primarily due to sales and marketing expenses associated with Gralise, which was launched in October 2011, and Zipsor which was acquired in June 2012. Operating expenses for the third quarter of 2012 also include $1.0 million of intangible amo
'/>"/>

SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
2. Depomed To Present At UBS Global Life Sciences Conference
3. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
4. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
6. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
7. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
8. Depomed To Present At Jefferies 2012 Global Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Cambrex Reports Third Quarter 2012 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK, Aug. 28, 2014 Reportlinker.com announces ... in its catalogue: North America Aesthetic ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Market Outlook to 2020", provides key market data ...
(Date:8/28/2014)... Aug. 28, 2014  Rigrodsky & Long, P.A.: , ... Inc. (NYSE: LCI )? , Did you purchase ... and July 16, 2014, inclusive? , Did you lose ... Do you want to discuss your rights? ... States Attorney, Timothy J. MacFall , announces that a complaint ...
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Testing Laboratories, Safety and Compliance Services ... Metrics and Revenue Forecasts to 2021, ... http://www.reportlinker.com/p02347353/Testing-Laboratories-Safety-and-Compliance-Services-Industry-US--Analytics-Extensive-Financial-Benchmarks-Metrics-and-Revenue-Forecasts-to-2021-NAIC-541380 .html Testing ...
Breaking Medicine Technology:North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6
(Date:8/28/2014)... 2014 Millennium Treatment Group is ... This month will be a celebration of the ... services. Along with other treatment facilities and mental ... spread the word about this national observance. , ... work of treatment and recovery professionals, and has ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Millennium ... use affecting users in the workplace. A recent ... Dependence (NCADD) states that drug abuse is costing ... who use or are addicted to drugs affect their ... activities carry over into the workplace, causing expensive problems ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... worsen symptoms of multiple sclerosis (MS), a new study from ... vitamin D, smoking and Epstein Barr virus infection. Our study ... affecting MS patients," said lead researcher Dr. Mauricio Farez, of ... Multiple sclerosis is a disease of the nervous system ...
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... August 28, 2014 Allegheny ... today a regional partnership designed to advance sports ... for competitive young athletes, scholastic athletes and their ... Strong Body & Mind Initiative will offer a ... the physical and mental dynamics involved in pursuing ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... N.C., Nov. 2 Just how much of the time,that ... due to,administrative tasks and internal communication? Pharmaceutical sales directors ... of the time used for internal communication - or 6 ... in lost sales every year,according to a recent research study ...
... HILL, N.C., Nov. 2 Records and Information,Management ... in the success of,their parent organizations through reducing ... Today the programs account for,over $1.5 million in ... leader,Best Practices, LLC. This number will continue ...
... each point scored, CENTENNIAL, Colo., Nov. 2 ... show support for their favorite team -- camping,out for ... for the big game. Now five football teams are ... of a deadly disease --,prostate cancer. The Denver ...
... Inc.,(Nasdaq: IDMI ) today announced the presentation of ... patients,with lung metastases as a result of the progression ... typically affects children and young,adults. The data show that ... exhibited signs of disease control. "These results are ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced ... for review the Company,s New Drug,Application (NDA) for NEBIDO(R), ... hypogonadism. The FDA Prescription,Drug User Fee Act (PDUFA) target ... was submitted to the FDA by the Company on ...
... Corporation,(Nasdaq: MNKD ), focused on discovering, developing and commercializing,treatments ... at,the following conferences: * The Acumen BioFin Rodman & ... November 6, 2007 at 2:20 PM ET at the New ... * The CIBC 18th Annual Healthcare Conference on Wednesday ...
Cached Medicine News:Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:New Records & Information Management: Are You Spending Right on Records Management, Data Security and Compliance? 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 2Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 3Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 4
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
Medicine Products: